FibroBiologics, Inc. Common Stock

FBLG

NASDAQ

Healthcare

Biotechnology

Houston, DE, US13 employeesfibrobiologics.com

$1.37

+0.04(2.99%)

Mkt Cap $3M

$1.32

$27.60

52-Week Range

At a Glance

AI-generated

8-K

FibroBiologics, Inc. implemented a 1-for-20 reverse stock split effective March 30, 2026, which proportionally reduced outstanding shares without altering stockholders' percentage ownership, except for fractional share adjustments.

$3M

Market Cap

—

Revenue

-$18M

Net Income

Employees13

Fundamentals

How The Business Makes Money

FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

Industry Biotechnology

Activity

What Changed Recently

Management Change

Mar 5, 2026

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 4, 2

Delisting

Feb 5, 2026

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on August 4, 2025, FibroBiologics,

Securities Modification

Apr 2, 2026

Material Modification to Rights of Security Holders. To the extent required by Item 3.03 of Form 8-K, the information regarding the Reverse Stock Split (as defi

Material Agreement

Apr 1, 2026

Entry into a Material Definitive Agreement. On March 31, 2026, FibroBiologics, Inc. (the “Company”) commenced a best-efforts public offering (the “Offering”) of

Shareholder Vote

Feb 22, 2026

Submission of Matters to a Vote of Security Holders. FibroBiologics, Inc. (the “Company”) held a Special Meeting of Stockholders on February 20, 2026 (the “Spec

Peer Companies

Company	Price	Change	Market Cap	P/E
LPTXLeap Therapeutics, Inc.	$0.77	-3.15%	$32M	-2.6
ATHAATHA	$6.75	-6.12%	$27M	—
DAREDaré Bioscience, Inc.	$1.75	-8.11%	$17M	-1.0
APLMApollomics, Inc.	$14.95	+1.53%	$16M	-0.6
ICUSeaStar Medical Holding C...	$4.46	+25.42%	$12M	-0.4
CTXRCitius Pharmaceuticals, I...	$0.85	+1.30%	$10M	-0.5
HOTHHoth Therapeutics, Inc.	$0.57	+3.25%	$7M	-1.1
AIMDAinos, Inc.	$1.44	+0.00%	$6M	-0.5

Analyst View

Company Profile

CIK0001958777

ISINUS31573L1052

CUSIP31573L105

Phone281 651 5150

Address455 East Medical Center Boulevard, Houston, DE, 77598, US

SEC EDGAR